Why the study?
Does HDL-C level correlate with the occurrence of MASLD in a Japanese population?
Cross-Sectional (n=14,280)
No
Does HDL-C level correlate with the occurrence of MASLD in a Japanese population?
Odds Ratio: 0.46 (95% CI 0.37–0.58)
There is a non-linear inverse relationship between HDL-C levels and MASLD prevalence in the Japanese population, with a protective threshold effect above 1.04 mmol/L.
Background Research into the effect of high-density lipoprotein cholesterol (HDL-C) on metabolic dysfunction-associated steatotic liver disease (MASLD) remains relatively limited. This research aims to shed light on how HDL-C levels correlate with MASLD among the Japanese demographic. Methods A comprehensive review of health records from 14,280 patients at Murakami Memorial Hospital from 2004 to 2015 was undertaken. To investigate the linear association of HDL-C concentrations with MASLD occurrence, binary logistic regression was applied. Additionally, a generalized additive model (GAM) integrated with smooth curve fitting procedures was implemented to characterize potential non-linear dependencies. Results An inverse correlation was observed between HDL-C levels and MASLD prevalence (OR = 0.46; 95% CI: 0.37–0.58), holding steady after adjustments for various demographic and health variables. The consistency of these findings was confirmed through multiple sensitivity tests. The study also uncovered a non-linear correlation between HDL-C concentrations and MASLD occurrence. A detailed analysis using a two-piece logistic regression and recursive techniques pinpointed a critical HDL-C level of 1.04 mmol/L. Above this level, each unit increase in HDL-C was linked to a 61% decrease in the likelihood of MASLD (OR = 0.39; 95% CI: 0.30–0.50), a connection that dissipates below this threshold of HDL-C (OR = 1.49; 95% CI: 0.66–3.35). Conclusion The investigation revealed an inverse, non-linear relationship between HDL-C and MASLD within the Japanese community, emphasizing a pivotal threshold effect. Elevated HDL-C levels beyond 1.04 mmol/L significantly diminish MASLD risk.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) conducted a cross-sectional in metabolic dysfunction-associated steatotic liver disease (MASLD) (n=14,280). High-density lipoprotein cholesterol (HDL-C) was evaluated on MASLD prevalence (OR 0.46, 95% CI 0.37-0.58).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: